Home Business Novavax to Present New COVID-19 Vaccine Candidate Data at New York Academy of...

Novavax to Present New COVID-19 Vaccine Candidate Data at New York Academy of Science

20
0
TheNFAPost Podcast
1

Bengaluru, NFAPost: Novavax Inc. (Nasdaq: NVAX), a biotech company known for its next-gen vaccines for serious infectious diseases, today announced that Gregory M. Glenn (M.D and President of Research & Development) will present on the company’s COVID-19 vaccine ‘NVX-CoV2373′, at The New York Academy of Science (NYAS) event, ‘The Quest for a COVID-19 Vaccine.’

Webinar details are as follows:

Presentation title: Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate
Date: February 2, 2021
Time: 4:00 pm ET
Presenter: Dr. Glenn

Novavax announced interim data last week on its protein-based COVID-19 vaccine candidate that demonstrated the efficacy of 89.3% in a pivotal Phase 3 clinical trial taking place in the United Kingdom (UK). The data from this UK Phase 3 trial and a South Africa Phase 2b study were the first to demonstrate clinical efficacy against newer circulating UK and South Africa COVID-19 variants.

To register for the webinar please visit the NYAS website. Presentation slides will be posted to the company’s website following the presentation here.

NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate nor can it cause COVID-19.

In preclinical studies, NVX-CoV2373 induced antibodies that block the binding of spike protein to cellular receptors and provided protection from infection and disease. It was generally well-tolerated and elicited robust antibody response numerically superior to that seen in human convalescent sera in Phase 1/2 clinical testing.

NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the U.K that completed enrollment in November and the PREVENT-19 trial in the U.S. and Mexico that began in December. It is also being tested in two ongoing Phase 2 studies that began in August: A Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.

Matrix-M

Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

For more information, visit www.novavax.com

Previous articleFKCCI Former President Lauds Bold Steps Proposed in Budget 2021-22
Next articleElectric Vehicle Fast-Charging System Market to be Worth USD 10.67bn by 2028

LEAVE A REPLY

Please enter your comment!
Please enter your name here